The Food and Drug Administration has approved garetosmab, a Regeneron antibody that will be sold as Pasatru, for fibrodysplasia ossificans progressiva — an ultra-rare condition in which muscle and connective tissue are gradually replaced by bone.
According to Endpoints News, the agency cleared the drug on Wednesday. The treatment works by targeting activin A, a signaling protein, using a lab-made antibody designed to interfere with the biological process that drives the abnormal bone growth.
FOP is debilitating precisely because the body builds a second skeleton where it shouldn't. As Endpoints News describes it, the disease turns tissue to bone, progressively locking down movement.
The commercial stakes are the second half of the story. BioPharma Dive reports that the approval sets up a market battle with Ipsen in a rare indication where the only available treatment has generated disappointing sales. In other words, Regeneron is entering a small patient population that already has an incumbent therapy — one that, by the trade publication's account, has underperformed commercially.
That combination is unusual. Drugmakers often avoid crowding into rare-disease niches, since the patient numbers are tiny and the development costs are not. A second approved option suggests Regeneron sees room to compete on the strength of its product rather than simply on being first.
For patients and families, the practical question now shifts to access: pricing, insurance coverage, and which patients doctors will consider appropriate candidates. None of that is settled by an approval alone.
Why it matters: for people living with a disease that slowly immobilizes them, having a second FDA-approved treatment means a real choice where, until now, there was essentially one.